Obesity and type 2 diabetes gets a promising data as announced by Genaera Corporation. They said that their drug candidate to treat obesity and type 2 diabetes, trodusquemine or MSI-1436, shows noticeable improvement in obese mice.
The same drug has also lowered the plasma insulin levels and improved the glucose tolerance and fasting blood glucose in animals that were hyperglycemic. This announcement was made at the Diabetes Mellitus Symposia in Breckenridge, Colorado.
In addition to the marked improvement in the aforementioned areas, the effects were maintained. Here's how they found this out. They administered the MSI-1436 to the diet-induced obese mice four weekly treatments. The result was significant in the sense that there was marked improvement in the level of plasma insulin.
In addition, the glucose tolerance improvement was maintained when the mice were administered the same drug weekly for 122 days. How did they find this out? By testing the oral glucose tolerance, and so they concluded that long periods of treatment will maintain the marked improvement for obesity and type 2 diabetes.
It looks like that the MSI-1436 has properties that are anti-diabetic. What are these properties? Maintained improvement in glucose tolerance and fasting blood glucose, improved sensitivity to insulin and lowering of plasma insulin levels are the anti-diabetic properties the scientists found from their experiments.
Genaera president and CEO Jack Armstrong said that with the promising data they obtained, they will keep on exploring MSI-1436 as a treatment for obesity and type 2 diabetes. They are going ahead with assessing the potential of this drug that will impact both obesity and type 2 diabetes.